menu
    • menu

    Company profile for SpyGlass Pharma

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    SpyGlass Pharma, co-founded by Dr. Malik Y. Kahook, MD, and Glenn Sussman, is dedicated to developing innovative treatments for chronic ophthalmic diseases. The company is built upon technology initially developed at the Sue Anschutz-Rodgers Eye Center of the University of Colorado School of Medicine. With a team comprising skilled engineers, scientists, and clinicians, SpyGlass Pharma focuses on creating transformative treatm...
    SpyGlass Pharma, co-founded by Dr. Malik Y. Kahook, MD, and Glenn Sussman, is dedicated to developing innovative treatments for chronic ophthalmic diseases. The company is built upon technology initially developed at the Sue Anschutz-Rodgers Eye Center of the University of Colorado School of Medicine. With a team comprising skilled engineers, scientists, and clinicians, SpyGlass Pharma focuses on creating transformative treatment options for patients with ophthalmic diseases. Their primary objective is to achieve long-term drug delivery solutions.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    SpyGlass PharmaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    27081 Aliso Creek Rd, Suite 125 Aliso Viejo, CA 92656
    Telephone
    Telephone
    +1 9492846904
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.spyglasspharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/spyglasspharma/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    euroPLX 90 Lisbon

    Not Confirmed

    envelop Contact Supplier

    euroPLX 90 Lisbon

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Spyglass Pharma Completes Ipo With Full Underwriters' Share
    Spyglass Pharma Completes Ipo With Full Underwriters' Share

    09 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/09/3234889/0/en/SpyGlass-Pharma-Announces-Closing-of-Initial-Public-Offering-and-Exercise-in-Full-of-the-Underwriters-Option-to-Purchase-Additional-Shares.html

    GLOBENEWSWIRE
    09 Feb 2026
    Share Share
    Agomab, Spyglass Head To Nasdaq With Ipos Totaling $350M
    Agomab, Spyglass Head To Nasdaq With Ipos Totaling $350M

    06 Feb 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/agomab-spyglass-head-nasdaq-ipos-totalling-350m

    FIERCE BIOTECH
    06 Feb 2026
    Share Share
    SpyGlass Pharma Announces Pricing Of Initial Public Offering
    SpyGlass Pharma Announces Pricing Of Initial Public Offering

    05 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/06/3233533/0/en/SpyGlass-Pharma-Announces-Pricing-of-Initial-Public-Offering.html

    GLOBENEWSWIRE
    05 Feb 2026
    Share Share
    Spyglass Pharma Initiates Phase III Trials For BIM-IOL System
    Spyglass Pharma Initiates Phase III Trials For BIM-IOL System

    20 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/20/3221657/0/en/SpyGlass-Pharma-Announces-First-Patients-Randomized-in-SGP-005-and-SGP-006-Two-Registrational-Phase-III-Clinical-Trials-of-Its-Novel-BIM-IOL-System.html

    GLOBENEWSWIRE
    20 Jan 2026
    Share Share
    Immunology Biotech Agomab, Eye-Focused Spyglass Share IPO Plans
    Immunology Biotech Agomab, Eye-Focused Spyglass Share IPO Plans

    19 Jan 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/immunology-biotech-agomab-eye-focused-spyglass-share-ipo-ambitions

    FIERCE BIOTECH
    19 Jan 2026
    Share Share
    Spyglass Pharma Names Jean-Frédéric Viret As CFO
    Spyglass Pharma Names Jean-Frédéric Viret As CFO

    06 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/06/3213577/0/en/SpyGlass-Pharma-Appoints-Jean-Fr%C3%A9d%C3%A9ric-Viret-as-Chief-Financial-Officer.html

    GLOBENEWSWIRE
    06 Jan 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search